Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis
Top Cited Papers
- 15 November 2007
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 357 (20) , 2028-2039
- https://doi.org/10.1056/nejmoa071408
Abstract
Bisphosphonate therapy is the current standard of care for the prevention and treatment of glucocorticoid-induced osteoporosis. Studies of anabolic therapy in patients who are receiving long-term glucocorticoids and are at high risk for fracture are lacking. In an 18-month randomized, double-blind, controlled trial, we compared teriparatide with alendronate in 428 women and men with osteoporosis (ages, 22 to 89 years) who had received glucocorticoids for at least 3 months (prednisone equivalent, 5 mg daily or more). A total of 214 patients received 20 μg of teriparatide once daily, and 214 received 10 mg of alendronate once daily. The primary outcome was the change in bone mineral density at the lumbar spine. Secondary outcomes included changes in bone mineral density at the total hip and in markers of bone turnover, the time to changes in bone mineral density, the incidence of fractures, and safety. At the last measurement, the mean (±SE) bone mineral density at the lumbar spine had increased more in the teriparatide group than in the alendronate group (7.2±0.7% vs. 3.4±0.7%, P<0.001). A significant difference between the groups was reached by 6 months (P<0.001). At 12 months, bone mineral density at the total hip had increased more in the teriparatide group. Fewer new vertebral fractures occurred in the teriparatide group than in the alendronate group (0.6% vs. 6.1%, P=0.004); the incidence of nonvertebral fractures was similar in the two groups (5.6% vs. 3.7%, P=0.36). Significantly more patients in the teriparatide group had at least one elevated measure of serum calcium. Among patients with osteoporosis who were at high risk for fracture, bone mineral density increased more in patients receiving teriparatide than in those receiving alendronate. (ClinicalTrials.gov number, NCT00051558.)Keywords
This publication has 35 references indexed in Scilit:
- Prevention and treatment strategies for glucocorticoid-induced osteoporotic fracturesClinical Rheumatology, 2006
- Longitudinal patterns in the prevention of osteoporosis in glucocorticoid‐treated patientsArthritis & Rheumatism, 2005
- A Meta-Analysis of Prior Corticosteroid Use and Fracture RiskJournal of Bone and Mineral Research, 2004
- Oral glucocorticoid use is associated with an increased risk of fractureOsteoporosis International, 2004
- The Epidemiology of Corticosteroid-Induced Osteoporosis: a Meta-analysisOsteoporosis International, 2002
- Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy.Calcified Tissue International, 2001
- Efficacy and Safety of Daily Risedronate in the Treatment of Corticosteroid-Induced Osteoporosis in Men and Women: A Randomized TrialJournal of Bone and Mineral Research, 2000
- Management of corticosteroid-induced osteoporosisSeminars in Arthritis and Rheumatism, 2000
- Risedronate therapy prevents corticosteroid-induced bone loss : A twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group studyArthritis & Rheumatism, 1999
- Alendronate for the Prevention and Treatment of Glucocorticoid-Induced OsteoporosisNew England Journal of Medicine, 1998